Status:
COMPLETED
Comparison of Insulin Detemir Plus Insulin Aspart Against Insulin Glargine Plus Insulin Aspart in Type 2 Diabetes
Lead Sponsor:
Novo Nordisk A/S
Conditions:
Diabetes
Diabetes Mellitus, Type 2
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
This trial is conducted in Europe and the United States of America (USA). The purpose of this study is to test whether insulin detemir is a safe and at least as effective alternative to insulin glargi...
Eligibility Criteria
Inclusion
- Type 2 diabetes for at least 12 months
- Treated with oral antidiabetic drugs or with any insulin regimen with or without oral antidiabetic drugs
- BMI of maximum 40 kg/m2
- HbA1c greater than or equal to 7.0% and less than or equal to 11.0%
Exclusion
- Proliferative retinopathy or maculopathy
- Recurrent major hypoglycaemia
- Impaired hepatic or renal function
- Cardiac problems or uncontrolled hypertension
Key Trial Info
Start Date :
September 1 2004
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2005
Estimated Enrollment :
324 Patients enrolled
Trial Details
Trial ID
NCT00097084
Start Date
September 1 2004
End Date
December 1 2005
Last Update
January 27 2017
Active Locations (60)
Enter a location and click search to find clinical trials sorted by distance.
1
Novo Nordisk Investigational Site
Little Rock, Arkansas, United States, 72204
2
Novo Nordisk Investigational Site
Inglewood, California, United States, 90301
3
Novo Nordisk Investigational Site
San Francisco, California, United States, 94143-0780
4
Novo Nordisk Investigational Site
Santa Ana, California, United States, 92705